$2.57T
Total marketcap
$179.05B
Total volume
BTC 50.05%     ETH 15.83%
Dominance

United Therapeutics UTHR Stock

233.97 USD {{ price }} -0.767664% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
11.01B USD
LOW - HIGH [24H]
229.72 - 237 USD
VOLUME [24H]
431.44K USD
{{ volume }}
P/E Ratio
11.80
Earnings per share
19.82 USD

United Therapeutics Price Chart

United Therapeutics UTHR Financial and Trading Overview

United Therapeutics stock price 233.97 USD
Previous Close 226.28 USD
Open 227.56 USD
Bid 0 USD x 1200
Ask 0 USD x 800
Day's Range 227 - 229.85 USD
52 Week Range 201.65 - 283.09 USD
Volume 229.23K USD
Avg. Volume 437.11K USD
Market Cap 10.76B USD
Beta (5Y Monthly) 0.604577
PE Ratio (TTM) 15.70383
EPS (TTM) 19.82 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 281 USD

UTHR Valuation Measures

Enterprise Value 8.54B USD
Trailing P/E 15.70383
Forward P/E 11.365841
PEG Ratio (5 yr expected) 1.28
Price/Sales (ttm) 5.4294276
Price/Book (mrq) 2.092737
Enterprise Value/Revenue 4.309
Enterprise Value/EBITDA 8.228

Trading Information

United Therapeutics Stock Price History

Beta (5Y Monthly) 0.604577
52-Week Change 4.65%
S&P500 52-Week Change 20.43%
52 Week High 283.09 USD
52 Week Low 201.65 USD
50-Day Moving Average 221.3 USD
200-Day Moving Average 238.36 USD

UTHR Share Statistics

Avg. Volume (3 month) 437.11K USD
Avg. Daily Volume (10-Days) 296.19K USD
Shares Outstanding 46.85M
Float 43.18M
Short Ratio 2.25
% Held by Insiders 1.75%
% Held by Institutions 98.92%
Shares Short 1.04M
Short % of Float 2.51%
Short % of Shares Outstanding 2.20%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 36.75%
Operating Margin (ttm) 49.73%
Gross Margin 91.01%
EBITDA Margin 52.36%

Management Effectiveness

Return on Assets (ttm) 10.52%
Return on Equity (ttm) 15.66%

Income Statement

Revenue (ttm) 1.98B USD
Revenue Per Share (ttm) 43.28 USD
Quarterly Revenue Growth (yoy) 9.70%
Gross Profit (ttm) 1.78B USD
EBITDA 1.04B USD
Net Income Avi to Common (ttm) 728.3M USD
Diluted EPS (ttm) 14.62
Quarterly Earnings Growth (yoy) 0.40%

Balance Sheet

Total Cash (mrq) 2.86B USD
Total Cash Per Share (mrq) 61.12 USD
Total Debt (mrq) 800M USD
Total Debt/Equity (mrq) 15.62 USD
Current Ratio (mrq) 9.837
Book Value Per Share (mrq) 109.708

Cash Flow Statement

Operating Cash Flow (ttm) 888.6M USD
Levered Free Cash Flow (ttm) 612.24M USD

Profile of United Therapeutics

Country United States
State MD
City Silver Spring
Address 1040 Spring Street
ZIP 20910
Phone 301 608 9292
Website https://www.unither.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 985

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Q&A For United Therapeutics Stock

What is a current UTHR stock price?

United Therapeutics UTHR stock price today per share is 233.97 USD.

How to purchase United Therapeutics stock?

You can buy UTHR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for United Therapeutics?

The stock symbol or ticker of United Therapeutics is UTHR.

Which industry does the United Therapeutics company belong to?

The United Therapeutics industry is Biotechnology.

How many shares does United Therapeutics have in circulation?

The max supply of United Therapeutics shares is 47.06M.

What is United Therapeutics Price to Earnings Ratio (PE Ratio)?

United Therapeutics PE Ratio is 11.80474300 now.

What was United Therapeutics earnings per share over the trailing 12 months (TTM)?

United Therapeutics EPS is 19.82 USD over the trailing 12 months.

Which sector does the United Therapeutics company belong to?

The United Therapeutics sector is Healthcare.

United Therapeutics UTHR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD